Dáil Éireann Debate, Wednesday - 17 April 2024
167. Deputy John McGuinness asked the Minister for Health if all cancer drug therapies available to Irish patients are universally and equitably available on the public system; and if he will make a statement on the matter. [16969/24]
Amharc ar fhreagraThe Health (Pricing and Supply of Medical Goods) Act 2013 provides a rigorous process for the assessment of new medicines for reimbursement. This allows taxpayers to be confident both that the right medicines are chosen, and that those medicines are approved at a price that can sustainably be afforded in a budget-limited health service. Economic assessment is valuable to stretch the funds granted to the HSE as far as possible, allowing them to provide a range of services as well as innovative medicines for all citizens.
The HSE has statutory responsibility for decisions on pricing and reimbursement of medicines under the 2013 Act. Reimbursement is for licensed indications which have been granted marketing authorisation by the European Medicines Agency (EMA) or the Health Products Regulatory Authority. In line with the 2013 Act, and the national framework agreed with industry, a company must first submit an application to the HSE to have a new medicine added to the reimbursement list.
All medicines which have been added to the reimbursement list, including cancer drug therapies, are available to eligible patients in the public health service.
